STTK Shattuck Labs, Inc.

NASDAQ
$4.47

Shattuck Labs, Inc. (STTK) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.5% since its last earnings release on November 5, 2026.

Shattuck Labs Missed Consensus Estimates
Thursday, November 5, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($0.13)
Rev est $1.1M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.66

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Shattuck Labs, Inc.

Shattuck Labs Inc. is a clinical-stage biotechnology company. It engages in development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The company's wholly owned program includes SL-172154. It operates principally in Durham, North Carolina and Austin, Texas. Shattuck Labs Inc. is based in Austin, United States.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.